Gradiant Bioconvergence, formerly known as Interpark Bioconvergence Corp. (IBCC),
is the one of earliest organizations developing patient-derived organoids (PDOs) in global scale.
Gradiant Bioconvergence's PDO banking with over 400 strains, co-culture platform with autologous T-cells, genetic-variation studies at whole-exome level, disease-modeling platform using CRISPR/Cas9
and novel growth-factors along ECMs for 3D culture provide leading opportunities for innovative partnership
in drug development, oncology research, and regenerative medicine.
2022
- 04 Gradiant Bioconvergence founded
2021
- 09 National Grant on organ-on-a-chip received
(in collaboration with Seoul National University College of Medicine)
2020
- 08 Interpark Bioconvergence Corp. founded
- 01 Collaboration agreement on organoid signed with Institute of Molecular Biotechnology (IMBA)
2019
- 12 License agreement signed with Hubrecht Organoid Technology (HUB)
- 10 Precision Medicine Center founded
(in collaboration with Severance Hospital) - 04 Collaboration agreement on decellularized extracellular matrix (dECM) signed with POSTECH
2018
- 02 MOU signed with Severance Hospital
2017
- 04 Interpark Bioconvergence Center founded
(in collaboration with International Vaccine Insitute)